TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37393120

Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus pomalidomide (SPd), n = 23
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus bortezomib (SVd), n = 16
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: selinexor+dexamethasone plus carfilzomib (SKd), n = 23
Number of subjects: 62

Group type: COMPARATOR
Intervention: selinexor+dexamethasone (Sd)
Number of subjects: 62
Study: 37393237

Group type: EXPERIMENTAL
Intervention: Adjuvanted inactivated influenza vaccine (aIIV3)
Number of subjects: 680

Group type: COMPARATOR
Intervention: High-dose inactivated influenza vaccine (HD-IIV3)
Number of subjects: 680
Study: 37393243

Group type: EXPERIMENTAL
Intervention: Knowledge of Advance Directives (PAD)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Knowledge of Health Care Proxy (HCP) role
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prior registration of PAD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, gender, education, job, marital status, internet access)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Religious beliefs (Non-Catholic)
Number of subjects: 120
Study: 37393269

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 37393272

Group type: EXPERIMENTAL
Intervention: Non-MetS group
Number of subjects: 52

Group type: COMPARATOR
Intervention: MetS group
Number of subjects: 52
Study: 37393278

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional phacoemulsification (CP)
Number of subjects: 126
Study: 37393359

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 37393415

Group type: EXPERIMENTAL
Intervention: ADAPT (Clinical Trial No. NCT04499079)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOME (Clinical Trial No. NCT04135703)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LeSA (Clinical Trial No. NCT04678960)
Number of subjects: 0
Study: 37393483

Group type: EXPERIMENTAL
Intervention: Regular exercise and eating fruits and vegetables
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Vaccination schedules
Number of subjects: 255
Study: 37393513

Group type: EXPERIMENTAL
Intervention: Higher dose of nusinersen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nusinersen levels in cerebrospinal fluid
Number of subjects: 6
Study: 37393568

Group type: EXPERIMENTAL
Intervention: Magnet Anastomosis System (MS) for side-to-side duodeno-ileostomy diversion
Number of subjects: 5
Study: 37393586

Group type: EXPERIMENTAL
Intervention: Higher pre-diagnostic low-fat dairy intake
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Higher pre- and post-diagnostic low-fat dairy intake
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Higher intakes of high-fat dairy
Number of subjects: 1812
Study: 37393658

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) stimulation
Number of subjects: 0
Study: 37393691

Group type: EXPERIMENTAL
Intervention: Itraconazole (ITZ) and hydroxyitraconazole (ITZ-OH) analysis using a validated LC-MS/MS method.
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Interference testing of over-the-counter and common co-administered medications.
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Incurred sample reanalysis (ISR) at the conclusion of the clinical study.
Number of subjects: 672
Study: 37393757

Group type: EXPERIMENTAL
Intervention: High VEGFR2 expression
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: High CD34 levels
Number of subjects: 333
Study: 37393762

Group type: EXPERIMENTAL
Intervention: KN046 3 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: KN046 5 mg/kg
Number of subjects: 64
Study: 37393802

Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a or IM interferon beta-1a
Number of subjects: 426
Study: 37394115

Group type: EXPERIMENTAL
Intervention: CART-B
Number of subjects: 135

Group type: COMPARATOR
Intervention: CART-A
Number of subjects: 135
Study: 37394178

Group type: EXPERIMENTAL
Intervention: FMXIN002 3.2 mg after nasal allergen challenge
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FMXIN002
Number of subjects: 12

Group type: COMPARATOR
Intervention: EpiPen (0.3 mg)
Number of subjects: 12
Study: 37394382

Group type: EXPERIMENTAL
Intervention: Envarsus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 100
Study: 37394389

Group type: EXPERIMENTAL
Intervention: Adhesive P (containing MDPB)
Number of subjects: 5102

Group type: COMPARATOR
Intervention: Adhesive S (control)
Number of subjects: 5102
Study: 37394507

Group type: EXPERIMENTAL
Intervention: Saliva-delivered PCR COVID-19 test
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Saliva sampling for COVID-19
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Alternate testing strategies
Number of subjects: 227
Study: 37394627

Group type: EXPERIMENTAL
Intervention: Adavosertib (225 mg bid) co-administration with cocktail
Number of subjects: 33
Study: 37394739

Group type: EXPERIMENTAL
Intervention: Conversation-based decision aid containing information about low-risk prostate cancer management options and their relative costs.
Number of subjects: 117
Study: 37394920

Group type: EXPERIMENTAL
Intervention: BMS-986141, a novel, oral, PAR4 agonist, administered as a single ascending dose.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 37395048

Group type: EXPERIMENTAL
Intervention: CT total-airway-count (TAC) measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Airway wall-thickness measurements
Number of subjects: 0
Study: 37395101

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Consultation liaison (CL)
Number of subjects: 691
Study: 37395169

Group type: EXPERIMENTAL
Intervention: Transcutaneous magnetic stimulation (TCMS) applied to each foot once a week for four weeks (n=18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment applied to each foot once a week for four weeks (n=16)
Number of subjects: 34
Study: 37395185

Group type: EXPERIMENTAL
Intervention: Activated recombinant FVII (rFVIIa) at a recommended dose of 15-30 μg/kg
Number of subjects: 20
Study: 37395254

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Integrase-strand transfer inhibitors (INSTIs)
Number of subjects: 2
Study: 37395286

Group type: EXPERIMENTAL
Intervention: Watchful waiting (WW) patients
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR) patients
Number of subjects: 313
Study: 37395501

Group type: EXPERIMENTAL
Intervention: Pre-oxygenation for 3 minutes
Number of subjects: 120
Study: 37395586

Group type: EXPERIMENTAL
Intervention: Culprit lesions (CL) with coronary microevaginations (CMEs)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Culprit lesions (CL) with intact fibrous cap (IFC) ACS
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: IFC-ICB (intact fibrous cap with no coronary bifurcation)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: IFC-ICB
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Culprit blood analysis in IFC-ICB
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Aspirated culprit thrombi in IFC-ICB
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: IFC-ACB (intact fibrous cap with association to a coronary bifurcation)
Number of subjects: 557
Study: 37395600

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural guided self-help (CBT-GSH)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Cognitive-analytic guided self-help (CAT-GSH)
Number of subjects: 271
Study: 37395780

Group type: EXPERIMENTAL
Intervention: Decompression surgery alone
Number of subjects: 988

Group type: COMPARATOR
Intervention: Decompression with instrumented fusion
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Natural course of LSS without planned surgical treatment
Number of subjects: 988
Study: 37395806

Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy (RDG)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 449
Study: 37395841

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 37395948

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dextrose hydrodissection (1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 1% normal saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dextrose hydrodissection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 40
Study: 37395974

Group type: EXPERIMENTAL
Intervention: Amlodipine, Losartan, Rosuvastatin, and Ezetimibe (A/L/R/E)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Amlodipine and Losartan (A/L)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Losartan, Rosuvastatin, and Ezetimibe (L/R/E)
Number of subjects: 145
Study: 37396126

Group type: EXPERIMENTAL
Intervention: Innovative synbiotics treatment for CKD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 37396307

Group type: EXPERIMENTAL
Intervention: Entecavir treatment for 78 weeks
Number of subjects: 394
Study: 37396569

Group type: EXPERIMENTAL
Intervention: Willingness to facilitate abortion care in eight hypothetical scenarios
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Facilitation of abortion care in the last 30 days
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Obstruction of abortion care in the last 30 days
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Association between stigma (SABAS score) and willingness to facilitate abortion care
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Association between stigma (SABAS score) and obstruction of abortion care
Number of subjects: 279
Study: 37396586

Group type: EXPERIMENTAL
Intervention: 3-dimensional (3D) printing technology for preoperative planning and guidance
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and guidance using 3D printing
Number of subjects: 1
Study: 37396590

Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Delayed stenting
Number of subjects: 123
Study: 37396805

Group type: EXPERIMENTAL
Intervention: B244 OD 5.0
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: B244 OD 20.0
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 547
Study: 37396808

Group type: EXPERIMENTAL
Intervention: CNM-Au8 (30 mg daily for 36 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (matching placebo daily for 36 weeks)
Number of subjects: 45
Study: 37396963

Group type: EXPERIMENTAL
Intervention: MLMC obesity intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 6
Study: 37397078

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - 3 cycles of 5-minute inflation of a blood pressure cuff to 15 mm Hg above systolic pressure before anthracycline therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 68
Study: 37397080

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 55
Study: 37397318

Group type: EXPERIMENTAL
Intervention: Physical fitness (PF)
Number of subjects: 490
Study: 37397433

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care at psychosocial intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 37397983

Group type: EXPERIMENTAL
Intervention: PPM-guided dosing of tacrolimus
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) clinician-determined dosing of tacrolimus
Number of subjects: 62
Study: 37397985

Group type: EXPERIMENTAL
Intervention: 2 μM simvastatin
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 426
Study: 37398014

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) delivered by Generation 2 providers
Number of subjects: 9
Study: 37398043

Group type: EXPERIMENTAL
Intervention: hrHPV detection (Xpert HPV, Cepheid)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Portable colposcopy (Gynocular, Gynius)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Combination of hrHPV testing followed by Gynocular
Number of subjects: 371
Study: 37398079

Group type: EXPERIMENTAL
Intervention: FDRs with pathogenic or likely pathogenic (P/LP) variants (n=39)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: FDRs with variants of uncertain significance (VUSs) (n=27)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Negative FDRs of probands without P/LP variants (n=30)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Negative FDRs of probands with pathogenic or likely pathogenic (P/LP) variants (n=28)
Number of subjects: 124
Study: 37398344

Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Optimal TMS regimen (to be determined in Phase 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham (Phase 2)
Number of subjects: 60
Study: 37398401

Group type: EXPERIMENTAL
Intervention: Interactive online training modules
Number of subjects: 82
Study: 37398623

Group type: EXPERIMENTAL
Intervention: Elagolix 25 mg twice daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Elagolix 50 mg once daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Elagolix 75 mg twice daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Elagolix (all doses)
Number of subjects: 114
Study: 37398685

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 37398686

Group type: EXPERIMENTAL
Intervention: Pre-transplantation risk assessment tool for graft survival
Number of subjects: 1428
Study: 37398992

Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 100 mg) oral once daily (DL1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg intravenously every 2 weeks and Dasatinib 60 mg/m2/dose (max 70 mg) twice daily (DL2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ganitumab 18 mg/kg every 2 weeks and Dasatinib 60 mg/m2/dose daily
Number of subjects: 13
Study: 37399002

Group type: EXPERIMENTAL
Intervention: FODMAPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gluten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 37399009

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: NHFOV
Number of subjects: 1137

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 1137
Study: 37399011

Group type: EXPERIMENTAL
Intervention: Stroke Ready intervention (combined ED and community components)
Number of subjects: 5970

Group type: EXPERIMENTAL
Intervention: ED component of the Stroke Ready intervention
Number of subjects: 5970

Group type: EXPERIMENTAL
Intervention: Community component of the Stroke Ready intervention
Number of subjects: 5970
Study: 37399054

Group type: EXPERIMENTAL
Intervention: TeNDER system
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 534
Study: 37399056

Group type: EXPERIMENTAL
Intervention: Kelaa Mental Resilience app for 4 weeks
Number of subjects: 532
Study: 37399066

Group type: EXPERIMENTAL
Intervention: eHealth care (remote patient monitoring and teleconsultation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 37399099

Group type: EXPERIMENTAL
Intervention: Highest quartiles of CCL19
Number of subjects: 4483

Group type: EXPERIMENTAL
Intervention: Highest quartiles of CCL21
Number of subjects: 4483

Group type: EXPERIMENTAL
Intervention: CCL19 and CCL21 added to conventional risk factors
Number of subjects: 4483

Group type: EXPERIMENTAL
Intervention: Major disability, death, and composite outcome of death or cardiovascular events
Number of subjects: 4483
Study: 37399108

Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 37399287

Group type: EXPERIMENTAL
Intervention: psy-RBD-FDRs
Number of subjects: 0

Group type: COMPARATOR
Intervention: psychiatric controls
Number of subjects: 0
Study: 37399355

Group type: EXPERIMENTAL
Intervention: APRIL CAR
Number of subjects: 11
Study: 37399357

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 274

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 274
Study: 37399447

Group type: EXPERIMENTAL
Intervention: Four different accommodation strategy components to compensate for cognitive dysfunction
Number of subjects: 256
Study: 37399456

Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg)
Number of subjects: 20
Study: 37399671

Group type: EXPERIMENTAL
Intervention: Wellness intervention (diet, stress reduction techniques, sleep hygiene, and exercise) delivered via a 7-week web-based program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 100
Study: 37399757

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) augmentation of exposure-based CBT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exposure-based CBT without DCS augmentation
Number of subjects: 59
Study: 37400140

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear incision technique with tissue preservation (LITT-P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MIPS
Number of subjects: 0

Group type: COMPARATOR
Intervention: LITT-P
Number of subjects: 0
Study: 37400162

Group type: EXPERIMENTAL
Intervention: Huachansu-TACE
Number of subjects: 120

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NKA-low group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NKA-high group
Number of subjects: 120
Study: 37400234

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 37400239

Group type: EXPERIMENTAL
Intervention: Customised insole with retrocapital bar and infracapital bar of the first metatarsal
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham insole
Number of subjects: 80
Study: 37400307

Group type: EXPERIMENTAL
Intervention: Dynamic computed tomography perfusion (CTP) analysis before and after successful CTO PCI
Number of subjects: 27
Study: 37400353

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor molecular subtypes
Number of subjects: 0
Study: 37400432

Group type: EXPERIMENTAL
Intervention: Stanford Neuromodulation Therapy (SNT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 37400554

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-Seq)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: WGS and RNA-Seq
Number of subjects: 91
Study: 37400561

Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital phototherapy
Number of subjects: 0
Study: 37400681

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study: 37400753

Group type: EXPERIMENTAL
Intervention: Multi-biomarker test (MBT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Xpert® TB Fingerstick cartridge
Number of subjects: 300

Group type: COMPARATOR
Intervention: Gold-standard composite TB outcome classification
Number of subjects: 300
Study: 37400758

Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention (education of health care personnel, access to standardized discontinuation regimens, patient education, support of transitional care)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 173
Study: 37400771

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich dietary pattern
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Protein-rich dietary pattern
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Unsaturated fat-rich dietary pattern
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Diet-related proteins
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Overall association
Number of subjects: 140

Group type: COMPARATOR
Intervention: ARIC study
Number of subjects: 140
Study: 37400806

Group type: EXPERIMENTAL
Intervention: Circulating DNA (cDNA) detection before potentiated radiotherapy and at 3 months post-treatment.
Number of subjects: 32
Study: 37400812

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Sb) 600 mg orally once daily for eight days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 37400828

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Optimal TMS regimen (to be determined in phase 1)
Number of subjects: 120
Study: 37400844

Group type: EXPERIMENTAL
Intervention: FCN-159 8 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FCN-159 12 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: FCN-159 (all doses)
Number of subjects: 19